Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder

American Journal of Psychiatry

Volumn 156, Issue 4, 1999, Pages 544-549

  Robinson, Delbert G ^a,b   Woerner, Margaret G ^a   Alvir, Jose Ma J ^a   Geisler, Stephen ^a   Koreen, Amy ^a   Sheitman, Brian ^a   Chakos, Miranda ^a   Mayerhoff, David ^a   Bilder, Robert ^a   Goldman, Robert ^a   Lieberman, Jeffrey A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; COGNITION; DELUSION; DRUG RESPONSE; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; PREDICTION; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA; SEX DIFFERENCE; SOCIAL INTERACTION; TREATMENT OUTCOME;

ADULT; ALGORITHMS; ANTIPSYCHOTIC AGENTS; FEMALE; HALLUCINATIONS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PREGNANCY; PREGNANCY COMPLICATIONS; PROBABILITY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032908294     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lieberman JA, Kinon BJ, Loebel AD: Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull 1990; 16:97-110
2. Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17:325-351
3. Longitudinal perspectives on the pathophysiology of schizophrenia: examining the neurodevelopmental versus neurodegenerative hypotheses. Schizophr Res 1991; 5:183-210
4. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149: 1183-1188
5. Olney JW, Farber NB: Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52:998-1007
6. Lieberman JA, Sheitman BB, Kinon BJ: Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997; 17:205-229
7. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M: Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993; 50:369-376
8. Koreen AR, Lieberman J, Alvir J, Mayerhoff D, Loebel A, Chakos M, Amin F, Cooper T: Plasma homovanillic acid levels in first-episode schizophrenia: psychopathology and treatment response. Arch Gen Psychiatry 1994; 51:132-138
9. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, Kane JM, Alvir J, Lieberman JA: Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995; 152:1724-1729
10. Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane JM, Borenstein M, Lieberman JA: Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996; 53:313-319
11. Lieberman JA, Alvir JM, Woerner M, Degreef G, Bilder R, Ashtari M, Bogerts B, Mayerhoff DI, Loebel A, Levy D, Hinrichsen G, Szymanski S, Chakos M, Borenstein M, Kane JM: Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophr Bull 1992; 18:351-371
12. Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders, 3rd ed. New York, New York State Psychiatric Institute, Biometrics Research, 1977
13. Endicott J, Spitzer RL: A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978; 35:837-844
14. Spitzer RL, Endicott J: Schedule for Affective Disorders and Schizophrenia - Change Version, 3rd ed. New York, New York State Psychiatric Institute, Biometrics Research, 1978
15. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare. 1976, pp 217-222
16. Andreasen NC, Olsen S: Negative v positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982; 39:789-794
17. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand (Suppl) 1970; 212:11-19
18. Simpson GM, Lee JH, Zoubok B, Gardos G: A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 1979; 64: 171-179
19. Cannon-Spoor HE, Potkin SG, Wyatt RJ: Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982; 8:470-484
20. McNeil TF, Cantor-Graae E, Sjöström K: Obstetric complications as antecedents of schizophrenia: empirical effects of using different obstetric complication scales. J Psychiatr Res 1994; 28:519-530
21. Ashtari M, Zito JL, Gold BI, Lieberman JA, Borenstein MT, Herman PG: Computerized volume measurement of brain structure. Invest Radiol 1990; 25:798-805
22. Bilder RM, Bogerts B, Ashtari M, Wu H, Alvir JM, Jody D, Reiter G, Bell L, Lieberman JA: Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr Res 1995; 17:47-58
23. Degreef G, Ashtari M, Bogerts B, Bilder RM, Jody DN, Alvir JMJ, Lieberman JA: Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. Arch Gen Psychiatry 1992; 49: 531-537
24. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, Wu H, Kinon B, Ashtari M: Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994; 151:1430-1436
25. Degreef G, Lantos G, Bogerts B, Ashtari M, Lieberman J: Abnormalities of the septum pellucidum on MR scans in first-episode schizophrenic patients. AJNR Am J Neuroradiol 1992; 13:835-840
26. Hollingshead AB: Two-Factor Index of Social Position. New Haven, Conn, Yale University, 1965
27. Kopala LC, Fredrikson D, Good KP, Honer WG: Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Biol Psychiatry 1996; 39:296-298
28. Scottish Schizophrenia Research Group: The Scottish First Episode Schizophrenia study, II: treatment: pimozide versus flupenthixol. Br J Psychiatry 1987; 150:334-338
29. McCreadie RG: Managing the first episode of schizophrenia: the role of new therapies. Eur Neuropsychopharmacol 1996; 6(2):S3-S5
30. Macmillan JF, Crow TJ, Johnson AL, Johnstone EC: Short-term outcome in trial entrants and trial eligible patients. Br J Psychiatry 1986; 148:128-133
31. Seeman MV: Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 1986; 73:609-617
32. Seeman MV: Gender differences in schizophrenia. Can J Psychiatry 1982; 27:107-112
33. Goldstein JM: Gender differences in the course of schizophrenia. Am J Psychiatry 1988; 145:684-689
34. Angermeyer MC, Kuhn L: Gender differences in age at onset of schizophrenia: an overview. Eur Arch Psychiatry Neurol Sci 1988; 237:351-364
35. Wilcox JA, Nasrallah HA: Perinatal distress and prognosis of psychotic illness. Biol Psychiatry 1987; 17:173-175
36. Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE: Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry 1996; 153:519-525
37. Cornblatt B, Obuchowski M, Schnur DB, O'Brien JD: Attention and clinical symptoms in schizophrenia. Psychiatr Q 1997; 68: 343-359